Alantra’s strategic partner Asabys launches a €200 million new fund to invest in pharma & healthtech

• The fund’s first closing is expected by the end of this year, with commitments from Alantra through its investment pool with Mutua Madrileña
• SAHII 2 will invest in pharma, medtech and digital health companies, developing disruptive solutions with solid scientific evidence to improve patient outcomes
• With this new vehicle Asabys consolidates itself as the leading venture capital firm in health technologies in Southern Europe

Barcelona – Alantra is pleased to announce that its strategic partner Asabys announced today the launch of a new fund, Sabadell Asabys Health Innovation Investments II (SAHII 2), to continue investing in health innovation technologies and consolidate its presence as leading venture capital firm in the space in Southern Europe.

Headquartered in Barcelona, Asabys was founded by Josep Ll. Sanfeliu and Clara Campàs in 2018 with the support of Alantra as strategic partner through the acquisition of a 35% stake in the firm.

Banc Sabadell, who was the anchor investor of the firm’s first fund, will also be the main private investor in this new vehicle. With a target size of €200 million, SAHII 2 aims to invest in European projects with disruptive technologies and solid scientific evidence, from early phases to commercialization stages.

With close to 120 million euros in AUM, Asabys has invested in 13 companies (1 exited) in the biopharma, medtech and digital health sectors. The experience acquired in these verticals positions Asabys as a unique firm diversifying its portfolio across biopharma and healthtech companies, generating synergies and acquiring unique know-how.

“Asabys was born with the mission to invest health innovation across the board and the reality is that the space has been converging technologically, creating countless opportunities to solve the challenges that medicine has nowadays by integrating biology or pharmacy with nanotechnologies, digitalization or artificial intelligence,” stated Josep Ll. Sanfeliu.

“With this second fund we will continue investing in the creation of new companies, as well as consolidate existing ones, with the goal to transform disruptive science in real solutions for patients,” added Clara Campàs.

“The investment of Banc Sabadell in SAHII 2 reflects the bank’s sustained commitment for innovation and emerging industries that provide impactful solutions to society, hand in hand with managers and teams that work with rigor and professionalism,” mentioned Raúl Rodríguez, Deputy Director General of Banc Sabadell and Director of BSCapital.